Trial Profile
AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms LIBERTY AD OLE
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 26 Feb 2024 Results (n=923) assessing the long-term efficacy of dupilumab for up to 5 years in adults with moderate-to-severe AD presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 02 Jul 2023 This trial has been completed in Estonia, according to European Clinical Trials Database record.
- 14 Nov 2022 Long-term safety results presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology